Dynavax Announces Second Quarter 2005 Financial Results Conference Call and Webcast
BERKELEY, Calif., July 14 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its second quarter 2005 financial results on Thursday, July 28, 2005 at 4:00 p.m. ET.
The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of second quarter 2005 financial results.
The webcast may be accessed on the Webcast page under the Investors tab on the Dynavax Technologies' website at http://www.dynavax.com.
The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
An audio replay of the webcast will be available until August 4, 2005, by dialing 888-286-8010; conference identification number 95875176. International callers can dial 617-801-6888; conference identification number 95875176.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: a ragweed allergy immunotherapeutic, currently in a large-scale Phase 2/3 clinical trial, and in a supportive clinical trial in ragweed allergic children; a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.
SOURCE Dynavax Technologies Corporation
07/14/2005
CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications,
of Dynavax Technologies Corporation, +1-510-665-4630 or jgreen@dvax.com
Web site: http://www.dynavax.com
(DVAX)
07/14/2005 16:00 EDT http://www.prnewswire.com